Athersys, Inc.

Equities

ATHXQ

US04744L2051

Biotechnology & Medical Research

Market Closed - OTC Markets 03:18:15 2024-03-28 pm EDT 5-day change 1st Jan Change
0.00604 USD +0.67% Intraday chart for Athersys, Inc. +3.45% -70.00%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Final DIP Financing Approved for Athersys, Inc. CI
Bidding Procedure Approved for Athersys, Inc. CI
Healios' Ischemic Stroke Trial Data Published in JAMA Neurology Journal MT
Interim DIP Financing Approved for Athersys, Inc. CI
Motion for Joint Administration Approved for Athersys, Inc. CI
Healios Steps In as Primary Bidder and Lender for Athersys’s Asset Sale Amidst Bankruptcy MT
Motion for Asset Sale Filed by Athersys, Inc. CI
Motion for Joint Administration Filed by Athersys, Inc. CI
Athersys, Inc. Filed for Bankruptcy CI
Healios K.K. entered into an asset purchase agreement to acquire Substantially all assets of ABT Holding Company, Advanced Biotherapeutics, Inc, Athersys, Inc. (OTCPK:ATHX.Q), ReGenesys BVBA and ReGenesys, LLC for $2.8 million. CI
Athersys, Inc. Announces Termination of Maia Hansen as Chief Operating Officer, Effective from December 31, 2023 CI
Athersys, Inc. Announces Termination of Daniel A. Camardo as Chief Executive Officer, Effective from December 31, 2023 CI
Athersys, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2023 CI
North American Morning Briefing : Caution Dominates Ahead of CPI Print DJ
Athersys Delisted from Nasdaq Risks Bankruptcy; Healios Remains Committed to Drug Development MT
Athersys, Inc.(OTCPK:ATHX) dropped from S&P TMI Index CI
Athersys, Inc.(OTCPK:ATHX) dropped from NASDAQ Composite Index CI
Athersys to Extend Liquidity with Warrant Inducement, Global ARDS License MT
Athersys Engages Outcome Capital to Assist with Evaluating Strategic Alternatives CI
Athersys, Inc. Reports Interim Analysis Results of MASTERS-2 Clinical Study with Multistem in Ischemic Stroke CI
Healios Secures Exclusive License for Cell Therapy Drug, Expanding Treatment for Acute Respiratory Distress Syndrome MT
Healios K.K. Enters into an Exclusive License Agreement with Athersys, Inc CI
Sector Update: Health Care Stocks Advancing Late Tuesday Afternoon MT
Top Midday Decliners MT
Sector Update: Health Care Stocks Rise in Afternoon Trading MT
Chart Athersys, Inc.
More charts
Athersys, Inc. is a biotechnology company focused primarily on the field of regenerative medicine. The Company is engaged in the discovery and development of therapeutic product candidates to address unmet medical needs in multiple disease areas. Its MultiStem (invimestrocel) cell therapy, which is an allogeneic stem cell product candidate, is its lead platform product and is in late-stage clinical development. MultiStem cell therapy includes treatment of critical care indications, neurological conditions, inflammatory and immune disorders, certain pulmonary conditions, cardiovascular disease, and other conditions. MultiStem cell therapy is manufactured from human stem cells obtained from adult bone marrow and these cells are alternatively obtained from other tissue sources. It is conducting a Phase III clinical trial of MultiStem cell therapy for the treatment of ischemic stroke, referred to as MultiStem Administration for Stroke Treatment and Enhanced Recovery Study-2 (MASTERS-2).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
  1. Stock
  2. Equities
  3. Stock Athersys, Inc. - OTC Markets
  4. News Athersys, Inc.
  5. Athersys to Make Changes to Ischemic Stroke Clinical Trial